Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia (AML) in which immature white blood cells called promyelocytes accumulate in the bone marrow instead of maturing into normal blood cells. It accounts for roughly 0.32 cases per 100,000 people each year. APL is both one of the most dangerous leukemias at the moment of diagnosis and one of the most curable with proper treatment, with five-year overall survival around 71% in real-world data and even higher in clinical trials.
What Happens Inside the Bone Marrow
APL starts with a specific genetic accident: a piece of chromosome 15 swaps places with a piece of chromosome 17. This swap, present in 90 to 95% of APL cases, fuses two genes together into a single abnormal gene. The protein this fusion gene produces jams the normal maturation process of promyelocytes. Instead of developing into functioning white blood cells, the promyelocytes stall at an immature stage and multiply unchecked. They crowd the bone marrow and spill into the bloodstream, leaving the body short on healthy blood cells.
The fusion protein also switches on genes that drive cell growth, compounding the problem. This is not just a buildup of useless cells. The abnormal promyelocytes actively interfere with normal blood clotting, which is why APL behaves so differently from other leukemias.
Symptoms and Warning Signs
Many APL symptoms overlap with other leukemias: fatigue, frequent infections, and pale skin from low red blood cell counts. What sets APL apart is its tendency to cause severe, unusual bleeding. The abnormal promyelocytes trigger a clotting crisis called disseminated intravascular coagulation (DIC), where the body simultaneously forms tiny clots throughout the bloodstream and depletes its clotting factors. The result is uncontrolled bleeding that can appear as heavy bruising, nosebleeds that won’t stop, bleeding gums, or blood in the urine or stool.
DIC is the single most dangerous complication of APL. Patients who develop it face nearly six times the risk of bleeding inside the brain and almost four times the risk of major bleeding overall. Intracranial hemorrhage and pulmonary hemorrhage are the leading causes of early death. About 10% of APL patients still die from bleeding complications in the early course of the disease, often before treatment has had time to work.
How APL Is Diagnosed
Doctors typically suspect APL based on how the bone marrow cells look under a microscope. The abnormal promyelocytes have a distinctive appearance, often packed with granules and sometimes containing bundles of needle-like structures called Auer rods. But appearance alone isn’t enough to confirm the diagnosis.
The gold-standard confirmation is a molecular test, most commonly fluorescence in situ hybridization (FISH), which directly identifies the chromosome 15;17 fusion. A technique called PCR can also detect the fusion gene’s RNA with high sensitivity. These molecular tests matter not just for initial diagnosis but for tracking the disease after treatment. Because APL is a medical emergency, treatment typically begins on suspicion alone, before molecular results come back.
Why APL Is Treated as an Emergency
Unlike most cancers, where a few days’ delay in starting treatment rarely changes the outcome, APL demands immediate action. The bleeding complications from DIC can become fatal within hours. When a doctor suspects APL based on blood work and cell appearance, the standard practice is to start a vitamin A derivative called all-trans retinoic acid (ATRA) right away, without waiting for genetic confirmation. ATRA forces the stalled promyelocytes to resume maturing, which quickly begins to ease the clotting crisis.
While waiting for the leukemia cells to respond, patients need aggressive supportive care. Blood products are transfused frequently to keep platelet counts and clotting factors at safe levels. Invasive procedures, even placing an IV line into a large vein, are avoided until the bleeding risk stabilizes, since any puncture can become a serious bleed.
Risk Categories at Diagnosis
Doctors categorize newly diagnosed APL patients into three risk groups using a simple model based on two blood counts at the time of diagnosis. High-risk patients have a white blood cell count above 10,000 per microliter. Those with white cells below 10,000 and platelets below 40,000 are considered intermediate risk. Low-risk patients have white cells below 10,000 and platelets above 40,000. The high-risk group faces the greatest chance of early death and complications, and their treatment is adjusted accordingly, often with the addition of chemotherapy alongside the standard regimen.
Standard Treatment
APL’s treatment story is one of the great successes in cancer medicine. Two drugs form the backbone of therapy: ATRA and arsenic trioxide (ATO). Neither is traditional chemotherapy. ATRA is derived from vitamin A and works by forcing immature leukemia cells to grow up into normal cells. ATO targets the abnormal fusion protein directly, breaking it down and killing the leukemia cells that depend on it.
Treatment unfolds in two phases. During induction, both drugs are given daily for roughly four to eight weeks, with the goal of eliminating visible leukemia from the bone marrow, a state called complete remission. Most patients achieve this. Consolidation follows, typically starting about a week after induction ends, and involves several cycles of both drugs spread over about seven months. For low- and intermediate-risk patients, ATRA plus ATO alone is often sufficient. High-risk patients may also receive chemotherapy during induction to bring down dangerously high white blood cell counts quickly.
Differentiation Syndrome
The very mechanism that makes ATRA and ATO effective, forcing leukemia cells to mature, can trigger a potentially serious side effect called differentiation syndrome. As large numbers of promyelocytes suddenly mature, they release inflammatory signals that cause fluid to leak into the lungs, the space around the heart, and other tissues. This affects roughly 16 to 25% of patients during induction.
The hallmark symptoms are breathing difficulty and fever, each occurring in about 80% of cases. About half of affected patients gain more than five kilograms from fluid retention or develop fluid around the lungs. Less commonly, it causes kidney failure (around 40%), fluid around the heart (20%), or dangerously low blood pressure (10 to 15%). Differentiation syndrome is treatable with steroids, and in severe cases, the ATRA or ATO is temporarily paused until the patient recovers.
Survival and Long-Term Outlook
For patients who survive the first few weeks, the long-term outlook is remarkably good. Real-world data show one-year survival of 81%, three-year survival of 75%, and five-year survival of 71%. The gap between one-year and five-year numbers reflects mostly early deaths from bleeding, not late relapses. Younger patients fare especially well: for those under 40, median overall survival was not even reached in large studies, meaning more than half were still alive at the end of the follow-up period. Patients between 41 and 60 had a median survival of 13.6 years, while those over 60 faced a shorter median of 4.5 years, largely due to greater vulnerability to early complications and other health conditions.
In clinical trials with optimal care, cure rates for low- and intermediate-risk APL now exceed 90%. The challenge in real-world settings is preventing those early deaths before treatment takes hold.
Monitoring After Treatment
Once a patient finishes consolidation, the fusion gene becomes the tracking signal for any remaining disease. A highly sensitive PCR test can detect as few as one leukemia cell among 10,000 normal cells. The standard recommendation is to test bone marrow samples every three months for the first three years after consolidation ends. The most important single time point is at the end of consolidation: if the fusion gene is undetectable at that point, the chances of long-term cure are excellent.
If the fusion gene reappears in two consecutive bone marrow tests, this is called molecular relapse, and treatment restarts before the leukemia becomes visible under a microscope. This strategy of catching relapse at the molecular level, before symptoms return, is one of the reasons APL’s cure rates are so high. Blood samples are less reliable for this monitoring because they lack the sensitivity to detect very low levels of residual disease. High-risk patients and those who still had detectable disease after induction benefit most from consistent monitoring through the full three-year window.